Q3

Indo Us Bio-Tech Ltd

INDOUSFY2511 Feb 2025

Revenue+6.3%

Net Profit+15.9%

OPM18.91%

P&L

Quarterly Standalone

Revenue

+6.3%23.56

Expenditure

+4.7%18.57

Net Profit

+15.9%5.05

NPM 21.43%+8.9%EPS ₹2.52+1045.5%

vs Q2 FY25

Informational and educational content only. Not investment advice.